This approach has been validated for B-cell lymphoma in a preclinical mouse model immunized with an adenovirus vector expressing A20 Id6 and will be tested in clinical trials against B-cell lymphomas using DNA vaccines encoding patient-specific Ids linked to immunostimulatory sequences29,30. This evidence concerns the gene IDS and B-cell non-Hodgkin lymphoma.